Cite
Myeloablative Conditioning with Alemtuzumab in Matched Related Donor Hematopoietic Cell Transplant for Sickle Cell Disease Prevents Graft-Versus-Host Disease without Compromising Engraftment.
MLA
John, Tami, et al. “Myeloablative Conditioning with Alemtuzumab in Matched Related Donor Hematopoietic Cell Transplant for Sickle Cell Disease Prevents Graft-Versus-Host Disease without Compromising Engraftment.” Biology of Blood & Marrow Transplantation, vol. 25, no. 3, Mar. 2019, p. S39. EBSCOhost, https://doi.org/10.1016/j.bbmt.2018.12.113.
APA
John, T., Yassine, K., Naik, S., Sasa, G., Omer, B., Martinez, C., Tewari, P., Krance, R. A., & Leung, K. S. (2019). Myeloablative Conditioning with Alemtuzumab in Matched Related Donor Hematopoietic Cell Transplant for Sickle Cell Disease Prevents Graft-Versus-Host Disease without Compromising Engraftment. Biology of Blood & Marrow Transplantation, 25(3), S39. https://doi.org/10.1016/j.bbmt.2018.12.113
Chicago
John, Tami, Khaled Yassine, Swati Naik, Ghadir Sasa, Bilal Omer, Caridad Martinez, Priti Tewari, Robert A. Krance, and Kathryn S Leung. 2019. “Myeloablative Conditioning with Alemtuzumab in Matched Related Donor Hematopoietic Cell Transplant for Sickle Cell Disease Prevents Graft-Versus-Host Disease without Compromising Engraftment.” Biology of Blood & Marrow Transplantation 25 (3): S39. doi:10.1016/j.bbmt.2018.12.113.